Čelakovská Jarmila, Čermáková Eva, Boudková Petra, Andýs Ctirad, Krejsek Jan
Department of Dermatology and Venereology, Faculty Hospital and Medical Faculty of Charles University, Hradec Králové, Czech Republic.
Department of Medical Biophysics, Medical Faculty of Charles University, Hradec Králové, Czech republic.
Immunol Med. 2025 Mar;48(1):33-46. doi: 10.1080/25785826.2024.2387882. Epub 2024 Aug 16.
Our aim is to determine the number of leukocytes, T lymphocytes and B lymphocytes and the expression of activation markers CD200 and CD23 on B lymphocytes in atopic dermatitis (AD) patients (treated and not treated with dupilumab) during the pollen season. We examined 29 patients not treated with dupilumab, 24 patients treated with dupilumab and 40 healthy subjects as a control group. The count of T and B lymphocytes and their subsets were assessed by flow cytometry. The non-parametric Kruskal-Wallis one-factor analysis of variance with post hoc by Dunn's test with Bonferroni's modification was used for statistical processing. Although there was a significant improvement in skin findings in patients treated with dupilumab, the changes in immunological profile show a persistent altered immune response characterized by dysregulation and overactivation of B lymphocytes. Dupilumab therapy leads to normalization of relative T regulatory lymphocytes and total memory B lymphocytes and to decreased count of absolute CD8 T lymphocytes. Studies investigating the immunological profile of atopic dermatitis (AD) patients during the pollen season are rare. There are no studies investigating the count of B lymphocytes (CD5, CD22 and CD73 B lymphocytes) and the expression of activation markers CD23 and CD200 on B lymphocytes and on their subsets during pollen season in AD patients treated and non-treated with dupilumab therapy.In atopic dermatitis (AD) patients with and without dupilumab therapy, we confirmed the significantly higher count of absolute neutrophils, absolute monocytes, absolute eosinophils, absolute basophils, non-switched B lymphocytes, transitional B lymphocytes, CD23 memory, naive, non-switched, switched and total CD23 B lymphocytes, the relative count of CD200 memory and CD200 switched B lymphocytes.In dupilumab treated patients, we confirmed the significantly higher count of relative eosinophils, relative CD16 eosinophils, relative CD200 non-switched B lymphocytes and lower count of absolute CD8 T lymphocytes. Further studies should focus on investigating the effect of dupilumab on CD8 T lymphocytes and their subpopulations.In patients without dupilumab therapy, we confirmed the significantly higher count of relative neutrophils, relative T regulatory lymphocytes and total memory B lymphocytes.The changes in the count of CD5, CD22 and CD73 B lymphocytes were not observed during pollen season in both groups of AD patients.
我们的目的是确定花粉季节期间特应性皮炎（AD）患者（接受和未接受度普利尤单抗治疗）的白细胞、T淋巴细胞和B淋巴细胞数量，以及B淋巴细胞上激活标志物CD200和CD23的表达。我们检查了29例未接受度普利尤单抗治疗的患者、24例接受度普利尤单抗治疗的患者以及40名健康受试者作为对照组。通过流式细胞术评估T和B淋巴细胞及其亚群的计数。采用非参数Kruskal-Wallis单因素方差分析，并通过Dunn检验和Bonferroni校正进行事后检验以进行统计处理。尽管接受度普利尤单抗治疗的患者皮肤症状有显著改善，但免疫谱的变化显示出持续改变的免疫反应，其特征为B淋巴细胞失调和过度激活。度普利尤单抗治疗可使相对调节性T淋巴细胞和总记忆B淋巴细胞恢复正常，并使绝对CD8 T淋巴细胞计数降低。研究花粉季节期间特应性皮炎（AD）患者免疫谱的研究很少。尚无研究调查接受和未接受度普利尤单抗治疗的AD患者在花粉季节期间B淋巴细胞（CD5、CD22和CD73 B淋巴细胞）的计数以及B淋巴细胞及其亚群上激活标志物CD23和CD200的表达。在接受和未接受度普利尤单抗治疗的特应性皮炎（AD）患者中，我们证实绝对中性粒细胞、绝对单核细胞、绝对嗜酸性粒细胞、绝对嗜碱性粒细胞、未转换B淋巴细胞、过渡性B淋巴细胞、CD23记忆性、幼稚、未转换、转换和总CD23 B淋巴细胞的计数显著更高，CD200记忆性和CD200转换B淋巴细胞的相对计数也显著更高。在接受度普利尤单抗治疗的患者中，我们证实相对嗜酸性粒细胞、相对CD16嗜酸性粒细胞、相对CD200未转换B淋巴细胞的计数显著更高，而绝对CD8 T淋巴细胞的计数更低。进一步的研究应侧重于调查度普利尤单抗对CD8 T淋巴细胞及其亚群的影响。在未接受度普利尤单抗治疗的患者中，我们证实相对中性粒细胞、相对调节性T淋巴细胞和总记忆B淋巴细胞的计数显著更高。在两组AD患者的花粉季节期间，均未观察到CD5、CD22和CD73 B淋巴细胞计数的变化。
